Exemestane

About

Therapy type: Hormone therapy

Therapy strategy: Aromatase inhibition

Mappings

NCI Thesaurus: Exemestane (coding:ncit:C1097)

RxNorm: exemestane (coding:rxcui:258494, coding:omop:1398399)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Organizations
Biomarkers
Cancer types
Therapies
Organizations Biomarkers Cancer types Therapies
EMA (1) FDA (2) ER positive, HER2-negative Invasive Breast Carcinoma Everolimus, Exemestane
EMA (1) FDA (2) HER2-negative, PR positive Invasive Breast Carcinoma Everolimus, Exemestane
EMA (1) FDA (2) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Everolimus, Exemestane
HSE (1) ER positive, PR positive Invasive Breast Carcinoma Exemestane
HPRA (1) HSE (1) ER positive Invasive Breast Carcinoma Exemestane
HSE (1) PR positive Invasive Breast Carcinoma Exemestane
EMA (1) FDA (2) HSE (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Exemestane
EMA (1) FDA (2) HSE (1) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Exemestane
EMA (1) FDA (2) HSE (1) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Exemestane
FDA (2) ER positive, HER2-positive Invasive Breast Carcinoma Exemestane, Palbociclib, Trastuzumab
FDA (2) HER2-positive, PR positive Invasive Breast Carcinoma Exemestane, Palbociclib, Trastuzumab
FDA (2) ER positive, HER2-positive Invasive Breast Carcinoma Exemestane, Palbociclib, Pertuzumab, Trastuzumab
FDA (2) HER2-positive, PR positive Invasive Breast Carcinoma Exemestane, Palbociclib, Pertuzumab, Trastuzumab